Amphion Innovations plc
Transfer of Shares
London and New York, 18 July 2016 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, today announces that it has drawn-down the additional tranche of US $750,000 (an “Additional Draw”), as announced on 13 July 2016, under the loan facility as initially announced on 5 June 2014 (the “Facility”). Under the terms of the Additional Draw, Amphion has pledged 1,400,000 Ordinary Shares of Motif Bio plc as additional collateral under the Facility. Amphion has now pledged a total of 16,306,145 Ordinary Shares of Motif Bio plc under the Facility.
For further information please contact
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 7382 1100
Plumtree Capital Limited (Financial Adviser)
+44 (0)20 7183 2493
+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.